A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab and Taxane Based Therapy

Trial Profile

A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab and Taxane Based Therapy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Oct 2017

At a glance

  • Drugs Trastuzumab emtansine (Primary) ; Atezolizumab
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms KATE2
  • Sponsors Roche
  • Most Recent Events

    • 27 Sep 2017 Status changed from recruiting to active, no longer recruiting.
    • 28 Aug 2017 Planned End Date changed from 5 Jun 2019 to 29 Aug 2019.
    • 11 Jul 2017 Planned End Date changed from 4 Jun 2019 to 5 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top